VA NORTHERN CALIFORNIA HEALTH CARE SYS
MATHER, CA
What changed
NIH I01 · Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer
Jan 2025Grant renewalJan 27, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 14 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
I01 · non-dilutive
Mar 1, 2024VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GAO, ALLEN C. · VA · award ends Feb 29, 2028 · Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer
NIH RePORTER · NIH RePORTER 11034085 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources